AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Heart Failure and Diabetogenic Risk with Atorvastatin 40 mg versus 80 mg in Stable CAD: A Large-Scale Real-World Evidence Study

By Htoo M, Kansagra V

Background: High-intensity statin therapy is recommended for secondary prevention in stable coronary artery disease (CAD). Heart failure (HF) is a major complication of stable CAD, with a 10-year cumulative incidence of approximately 25% in patients with coronary heart disease. In the CLARIFY registry, 16.4% of outpatients with chronic coronary syndrome developed cardiovascular death, HF hospitalization, or new-onset HF over 5 years. However, high-intensity statins are associated with a dose-dependent increase in new-onset type 2 diabetes mellitus (T2DM), with a 36% proportional increase reported in the CTT Collaboration meta-analysis. The TNT trial demonstrated that atorvastatin 80 mg reduced heart failure (HF) hospitalization by 26% compared to 10 mg. No study has directly compared atorvastatin 40 mg versus 80 mg for both HF and T2DM outcomes. Methods: Retrospective propensity score-matched cohort study using the TriNetX US Collaborative Network (68 healthcare organizations). Adults ≥18 years with stable CAD (ICD-10: I25.10) receiving atorvastatin 40 mg (Cohort 1) or 80 mg (Cohort 2) within 10 years of diagnosis were included; other statin users were excluded. Propensity score matching balanced demographics, comorbidities, prior revascularization, and lipid values. Primary outcome was incident HF; secondary outcome was new-onset T2DM. Patients with the outcome prior to the index event were excluded. Results: After matching, 176,262 patients were included per cohort (mean age 65.9 years; 71% male). Incident HF occurred in 19.2% on atorvastatin 40 mg versus 20.3% on 80 mg (risk ratio [RR] 0.95, 95% CI 0.93-0.96; p<0.001; HR 1.02, 95% CI 1.01-1.04; log-rank p=0.013). New-onset T2DM occurred in 12.1% versus 12.8% (RR 0.94, 95% CI 0.92-0.96; p<0.001; HR 1.02, 95% CI 1.00-1.05; log-rank p=0.053). Both outcomes favored atorvastatin 40 mg over 80 mg in this real-world cohort. Conclusion: Atorvastatin 40 mg was associated with modestly lower rates of both incident HF and new-onset T2DM compared to 80 mg. The T2DM finding is consistent with the established dose-dependent diabetogenic effect of atorvastatin observed across the TNT, IDEAL, and SPARCL trials. The HF finding, however, contrasts with the TNT trial, in which atorvastatin 80 mg reduced HF hospitalization by 26% versus 10 mg. This discordance likely reflects indication bias inherent to retrospective data, as higher-risk patients are preferentially prescribed 80 mg. Additionally, the 2026 ACC/AHA Dyslipidemia Guidelines note that statin benefit in HF remains uncertain, with large RCTs (CORONA, GISSI-HF) showing no significant HF benefit from statin therapy alone. Prospective studies directly comparing atorvastatin 40 mg versus 80 mg with HF, T2DM, and mortality endpoints are warranted to clarify the optimal statin intensity in stable CAD.

doi.org/10.1161/circ.154.suppl_1.7178Interventions

AgingResearch.News